156 related articles for article (PubMed ID: 26872727)
1. Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.
Grimm D; Lieb J; Weyer V; Vollmar J; Darstein F; Lautem A; Hoppe-Lotichius M; Koch S; Schad A; Schattenberg JM; Wörns MA; Weinmann A; Galle PR; Zimmermann T
BMC Cancer; 2016 Feb; 16():94. PubMed ID: 26872727
[TBL] [Abstract][Full Text] [Related]
2. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.
Chen W; Xiao W; Zhang K; Yin X; Lai J; Liang L; Chen D
Sci Rep; 2016 Mar; 6():22976. PubMed ID: 26964667
[TBL] [Abstract][Full Text] [Related]
3. The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.
Geier A; Macias RI; Bettinger D; Weiss J; Bantel H; Jahn D; Al-Abdulla R; Marin JJ
Oncotarget; 2017 Feb; 8(9):15846-15857. PubMed ID: 28178663
[TBL] [Abstract][Full Text] [Related]
4. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
[TBL] [Abstract][Full Text] [Related]
5. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
6. Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma.
Xu J; Liang J; Meng YM; Yan J; Yu XJ; Liu CQ; Xu L; Zhuang SM; Zheng L
Clin Cancer Res; 2017 Aug; 23(15):4482-4492. PubMed ID: 28223275
[No Abstract] [Full Text] [Related]
7. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Sohn W; Paik YH; Cho JY; Lim HY; Ahn JM; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
J Hepatol; 2015 May; 62(5):1112-21. PubMed ID: 25514557
[TBL] [Abstract][Full Text] [Related]
8. Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs.
Shi Y; Huang A
Tumour Biol; 2015 Nov; 36(11):8455-63. PubMed ID: 26026584
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
10. Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma.
Soto M; Reviejo M; Al-Abdulla R; Romero MR; Macias RIR; Boix L; Bruix J; Serrano MA; Marin JJG
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165687. PubMed ID: 31953214
[TBL] [Abstract][Full Text] [Related]
11. High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
Lin TH; Shao YY; Chan SY; Huang CY; Hsu CH; Cheng AL
Clin Cancer Res; 2015 Aug; 21(16):3678-84. PubMed ID: 25977342
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
[TBL] [Abstract][Full Text] [Related]
13. RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis.
Zhou T; Lv X; Guo X; Ruan B; Liu D; Ding R; Gao Y; Ding J; Dou K; Chen Y
Oncol Rep; 2015 Jun; 33(6):3006-14. PubMed ID: 25901709
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
16. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
Tomonari T; Takeishi S; Taniguchi T; Tanaka T; Tanaka H; Fujimoto S; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T
Oncotarget; 2016 Feb; 7(6):7207-15. PubMed ID: 26769852
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
18. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
Negri FV; Dal Bello B; Porta C; Campanini N; Rossi S; Tinelli C; Poggi G; Missale G; Fanello S; Salvagni S; Ardizzoni A; Maria SE
Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
[TBL] [Abstract][Full Text] [Related]
19. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Ishijima N; Kanki K; Shimizu H; Shiota G
Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
[TBL] [Abstract][Full Text] [Related]
20. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
